pharmaobservatory 0.1.5 → 0.1.7

This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
Files changed (647) hide show
  1. checksums.yaml +4 -4
  2. data/README.md +379 -7
  3. data/docs/BiomarkerAssayEvidenceResponse.md +58 -0
  4. data/docs/{BiomarkerCdxAssertionsResponseBuild.md → BiomarkerAssayEvidenceResponseBuild.md} +2 -2
  5. data/docs/{BiomarkerCdxAssertionsResponseFreshness.md → BiomarkerAssayEvidenceResponseFreshness.md} +2 -2
  6. data/docs/{BiomarkerCdxAssertionsResponseScope.md → BiomarkerAssayEvidenceResponseScope.md} +2 -2
  7. data/docs/BiomarkerAssayEvidenceRow.md +68 -0
  8. data/docs/BiomarkerAssayWhitespaceResponse.md +58 -0
  9. data/docs/BiomarkerAssayWhitespaceRow.md +66 -0
  10. data/docs/BiomarkerBqpAssertionsResponse.md +3 -3
  11. data/docs/BiomarkerCdxAssertionsResponse.md +3 -3
  12. data/docs/BiomarkerEvidenceResponse.md +3 -3
  13. data/docs/BiomarkerLiteratureResponse.md +3 -3
  14. data/docs/BiomarkerPublishingCompaniesResponse.md +3 -3
  15. data/docs/BiomarkerPublishingCompaniesRow.md +9 -1
  16. data/docs/BiomarkerRelationsResponse.md +3 -3
  17. data/docs/BiomarkerSampleCoverageResponse.md +3 -3
  18. data/docs/BiomarkerSamplePrevalenceResponse.md +3 -3
  19. data/docs/BiomarkerValidationResponse.md +3 -3
  20. data/docs/BiomarkerVariantMentionsResponse.md +3 -3
  21. data/docs/BiomarkersApi.md +160 -0
  22. data/docs/BiomarkersRecord.md +2 -2
  23. data/docs/BiomarkersResponse.md +3 -3
  24. data/docs/BiomarkersRow.md +2 -0
  25. data/docs/BrandCompaniesResponse.md +58 -0
  26. data/docs/BrandCompaniesRow.md +50 -0
  27. data/docs/BrandRevenueResponse.md +58 -0
  28. data/docs/BrandRevenueRow.md +60 -0
  29. data/docs/CatalystsResponse.md +58 -0
  30. data/docs/CatalystsRow.md +90 -0
  31. data/docs/CellLinesRecord.md +2 -2
  32. data/docs/CellLinesResponse.md +3 -3
  33. data/docs/CliaCertificatesResponse.md +58 -0
  34. data/docs/CliaCertificatesRow.md +80 -0
  35. data/docs/CompaniesApi.md +1947 -143
  36. data/docs/CompaniesRecord.md +2 -2
  37. data/docs/CompaniesRecordAttributes.md +3 -1
  38. data/docs/CompaniesResponse.md +3 -3
  39. data/docs/CompaniesRow.md +1 -1
  40. data/docs/CompanyAssetsResponse.md +3 -3
  41. data/docs/CompanyFundingEventsResponse.md +3 -3
  42. data/docs/CompanyFundingEventsRow.md +3 -1
  43. data/docs/CompanyFundingSummaryResponse.md +3 -3
  44. data/docs/CompanyMembersResponse.md +3 -3
  45. data/docs/CompanyProgramsResponse.md +3 -3
  46. data/docs/CompanyTargetsResponse.md +3 -3
  47. data/docs/CompanyTargetsRow.md +5 -1
  48. data/docs/CompanyTrialGeographyResponse.md +58 -0
  49. data/docs/CompanyTrialGeographyRow.md +52 -0
  50. data/docs/CompanyTrialSitesResponse.md +58 -0
  51. data/docs/CompanyTrialSitesRow.md +52 -0
  52. data/docs/ConditionAdverseEventsResponse.md +3 -3
  53. data/docs/ConditionBurdenResponse.md +3 -3
  54. data/docs/ConditionDeliveryResponse.md +3 -3
  55. data/docs/ConditionDrugsResponse.md +3 -3
  56. data/docs/ConditionPrevalenceResponse.md +3 -3
  57. data/docs/ConditionPrevalenceRow.md +1 -1
  58. data/docs/ConditionPublicationsResponse.md +3 -3
  59. data/docs/ConditionRecruitmentByPhaseResponse.md +58 -0
  60. data/docs/ConditionRecruitmentByPhaseRow.md +50 -0
  61. data/docs/ConditionRecruitmentDurationResponse.md +58 -0
  62. data/docs/ConditionRecruitmentDurationRow.md +86 -0
  63. data/docs/ConditionSitesResponse.md +3 -3
  64. data/docs/ConditionTrialStartForecastResponse.md +58 -0
  65. data/docs/ConditionTrialStartForecastRow.md +70 -0
  66. data/docs/ConditionTrialsResponse.md +3 -3
  67. data/docs/ConditionTrialsRow.md +1 -1
  68. data/docs/ConditionsApi.md +560 -0
  69. data/docs/ConditionsRecord.md +2 -2
  70. data/docs/ConditionsRecordAttributes.md +3 -1
  71. data/docs/ConditionsResponse.md +3 -3
  72. data/docs/CroFootprintResponse.md +58 -0
  73. data/docs/CroFootprintRow.md +34 -0
  74. data/docs/CroTrialsResponse.md +58 -0
  75. data/docs/CroTrialsRow.md +46 -0
  76. data/docs/DebarmentsResponse.md +58 -0
  77. data/docs/DebarmentsRow.md +44 -0
  78. data/docs/DrugApprovalsResponse.md +58 -0
  79. data/docs/DrugApprovalsRow.md +28 -0
  80. data/docs/DrugAspCodesResponse.md +58 -0
  81. data/docs/DrugAspCodesRow.md +28 -0
  82. data/docs/DrugBrandsResponse.md +58 -0
  83. data/docs/DrugBrandsRow.md +60 -0
  84. data/docs/DrugCombinationsResponse.md +58 -0
  85. data/docs/DrugCombinationsRow.md +32 -0
  86. data/docs/DrugDeclaredPatentsResponse.md +58 -0
  87. data/docs/DrugDeclaredPatentsRow.md +58 -0
  88. data/docs/DrugLabelSafetyResponse.md +58 -0
  89. data/docs/DrugLabelSafetyRow.md +32 -0
  90. data/docs/DrugMedicareSpendResponse.md +58 -0
  91. data/docs/DrugMedicareSpendRow.md +28 -0
  92. data/docs/DrugPatentCliffResponse.md +3 -3
  93. data/docs/DrugPatentCliffRow.md +3 -1
  94. data/docs/DrugPatentMentionsResponse.md +58 -0
  95. data/docs/DrugPatentMentionsRow.md +28 -0
  96. data/docs/DrugPatentOwnersResponse.md +58 -0
  97. data/docs/DrugPatentOwnersRow.md +42 -0
  98. data/docs/DrugPricingResponse.md +58 -0
  99. data/docs/DrugPricingRow.md +32 -0
  100. data/docs/DrugRecallsResponse.md +58 -0
  101. data/docs/DrugRecallsRow.md +34 -0
  102. data/docs/DrugRegulatoryResponse.md +58 -0
  103. data/docs/DrugRegulatoryRow.md +38 -0
  104. data/docs/DrugSitesResponse.md +58 -0
  105. data/docs/DrugSitesRow.md +28 -0
  106. data/docs/DrugTargetsResponse.md +58 -0
  107. data/docs/DrugTargetsRow.md +36 -0
  108. data/docs/DrugTrialConditionsResponse.md +58 -0
  109. data/docs/DrugTrialConditionsRow.md +30 -0
  110. data/docs/DrugTrialsResponse.md +58 -0
  111. data/docs/DrugTrialsRow.md +58 -0
  112. data/docs/DrugVariantsResponse.md +58 -0
  113. data/docs/DrugVariantsRow.md +38 -0
  114. data/docs/DrugsApi.md +2153 -0
  115. data/docs/DrugsRecord.md +38 -0
  116. data/docs/DrugsRecordAttributes.md +20 -0
  117. data/docs/DrugsResponse.md +58 -0
  118. data/docs/DrugsRow.md +82 -0
  119. data/docs/EnforcementEventsResponse.md +58 -0
  120. data/docs/EnforcementEventsRow.md +64 -0
  121. data/docs/GxpFacilitiesResponse.md +58 -0
  122. data/docs/GxpFacilitiesRow.md +152 -0
  123. data/docs/HospitalBedsYearlyResponse.md +58 -0
  124. data/docs/HospitalBedsYearlyRow.md +28 -0
  125. data/docs/HospitalFacilityChangesResponse.md +58 -0
  126. data/docs/HospitalFacilityChangesRow.md +30 -0
  127. data/docs/HospitalsApi.md +393 -0
  128. data/docs/HospitalsRecord.md +38 -0
  129. data/docs/HospitalsResponse.md +58 -0
  130. data/docs/HospitalsRow.md +40 -0
  131. data/docs/ImportRefusalsResponse.md +58 -0
  132. data/docs/ImportRefusalsRow.md +60 -0
  133. data/docs/InspectionFindingsResponse.md +58 -0
  134. data/docs/InspectionFindingsRow.md +48 -0
  135. data/docs/InspectionsResponse.md +58 -0
  136. data/docs/InspectionsRow.md +60 -0
  137. data/docs/InstitutionalHoldingsResponse.md +3 -3
  138. data/docs/InstitutionalHoldingsRow.md +7 -1
  139. data/docs/InstitutionalQuarterTotalsResponse.md +58 -0
  140. data/docs/InstitutionalQuarterTotalsRow.md +58 -0
  141. data/docs/InvestorFundsResponse.md +58 -0
  142. data/docs/InvestorFundsRow.md +24 -0
  143. data/docs/InvestorPortfolioResponse.md +58 -0
  144. data/docs/InvestorPortfolioRow.md +42 -0
  145. data/docs/InvestorPrivateFundsResponse.md +58 -0
  146. data/docs/InvestorPrivateFundsRow.md +44 -0
  147. data/docs/InvestorsApi.md +633 -0
  148. data/docs/InvestorsRecord.md +38 -0
  149. data/docs/InvestorsResponse.md +58 -0
  150. data/docs/InvestorsRow.md +54 -0
  151. data/docs/LegalEntitiesApi.md +1595 -155
  152. data/docs/LegalEntitiesRecord.md +2 -2
  153. data/docs/LegalEntitiesRecordAttributes.md +2 -0
  154. data/docs/LegalEntitiesResponse.md +3 -3
  155. data/docs/LegalEntitiesRow.md +1 -1
  156. data/docs/ManagersApi.md +233 -0
  157. data/docs/ManagersRecord.md +38 -0
  158. data/docs/ManagersResponse.md +58 -0
  159. data/docs/ManagersRow.md +46 -0
  160. data/docs/OrgDisclosuresResponse.md +58 -0
  161. data/docs/OrgDisclosuresRow.md +56 -0
  162. data/docs/OrgRelationshipsResponse.md +58 -0
  163. data/docs/OrgRelationshipsRow.md +68 -0
  164. data/docs/OwnershipPercentagesResponse.md +58 -0
  165. data/docs/OwnershipPercentagesRow.md +74 -0
  166. data/docs/OwnershipPositionsResponse.md +3 -3
  167. data/docs/OwnershipPositionsRow.md +16 -14
  168. data/docs/PdufaDatesResponse.md +3 -3
  169. data/docs/PdufaDatesRow.md +1 -1
  170. data/docs/ProgramLicensingCandidatesResponse.md +58 -0
  171. data/docs/ProgramLicensingCandidatesRow.md +58 -0
  172. data/docs/ProgramsResponse.md +58 -0
  173. data/docs/ProgramsRow.md +46 -0
  174. data/docs/RareDiseaseGenesResponse.md +58 -0
  175. data/docs/RareDiseaseGenesRow.md +50 -0
  176. data/docs/RareDiseaseHierarchyResponse.md +58 -0
  177. data/docs/RareDiseaseHierarchyRow.md +40 -0
  178. data/docs/RareDiseaseInvestigatorCoverageResponse.md +58 -0
  179. data/docs/RareDiseaseInvestigatorCoverageRow.md +38 -0
  180. data/docs/RareDiseaseInvestigatorsResponse.md +58 -0
  181. data/docs/RareDiseaseInvestigatorsRow.md +56 -0
  182. data/docs/RareDiseaseMappingsResponse.md +58 -0
  183. data/docs/RareDiseaseMappingsRow.md +44 -0
  184. data/docs/RareDiseaseOrganizationsResponse.md +58 -0
  185. data/docs/RareDiseaseOrganizationsRow.md +60 -0
  186. data/docs/RareDiseasePrevalenceResponse.md +58 -0
  187. data/docs/RareDiseasePrevalenceRow.md +62 -0
  188. data/docs/RareDiseaseRarityEvidenceResponse.md +58 -0
  189. data/docs/RareDiseaseRarityEvidenceRow.md +36 -0
  190. data/docs/RareDiseaseRarityResponse.md +58 -0
  191. data/docs/RareDiseaseRarityRow.md +54 -0
  192. data/docs/RareDiseaseReplacementsResponse.md +58 -0
  193. data/docs/RareDiseaseReplacementsRow.md +40 -0
  194. data/docs/RareDiseaseSiteCoverageResponse.md +58 -0
  195. data/docs/RareDiseaseSiteCoverageRow.md +54 -0
  196. data/docs/RareDiseaseSponsorsResponse.md +58 -0
  197. data/docs/RareDiseaseSponsorsRow.md +82 -0
  198. data/docs/RareDiseaseTrialCoverageResponse.md +58 -0
  199. data/docs/RareDiseaseTrialCoverageRow.md +58 -0
  200. data/docs/RareDiseaseTrialSitesResponse.md +58 -0
  201. data/docs/RareDiseaseTrialSitesRow.md +52 -0
  202. data/docs/RareDiseaseTrialsResponse.md +58 -0
  203. data/docs/RareDiseaseTrialsRow.md +90 -0
  204. data/docs/RareDiseasesApi.md +1353 -0
  205. data/docs/RareDiseasesRecord.md +38 -0
  206. data/docs/RareDiseasesRecordAttributes.md +22 -0
  207. data/docs/RareDiseasesResponse.md +58 -0
  208. data/docs/RareDiseasesRow.md +68 -0
  209. data/docs/RecallsResponse.md +58 -0
  210. data/docs/RecallsRow.md +54 -0
  211. data/docs/RwdCoverageResponse.md +58 -0
  212. data/docs/RwdCoverageRow.md +52 -0
  213. data/docs/RwdRegisterProvenanceResponse.md +58 -0
  214. data/docs/RwdRegisterProvenanceRow.md +74 -0
  215. data/docs/RwdRegistersApi.md +313 -0
  216. data/docs/RwdRegistersRecord.md +38 -0
  217. data/docs/RwdSourceAgeBandsResponse.md +58 -0
  218. data/docs/RwdSourceAgeBandsRow.md +40 -0
  219. data/docs/RwdSourceConditionsResponse.md +58 -0
  220. data/docs/RwdSourceConditionsRow.md +68 -0
  221. data/docs/RwdSourceEtlMappingsResponse.md +58 -0
  222. data/docs/RwdSourceEtlMappingsRow.md +44 -0
  223. data/docs/RwdSourceLinkagesResponse.md +58 -0
  224. data/docs/RwdSourceLinkagesRow.md +64 -0
  225. data/docs/RwdSourceTypesResponse.md +58 -0
  226. data/docs/RwdSourceTypesRow.md +34 -0
  227. data/docs/RwdSourceVocabulariesResponse.md +58 -0
  228. data/docs/RwdSourceVocabulariesRow.md +42 -0
  229. data/docs/RwdSourcesApi.md +713 -0
  230. data/docs/RwdSourcesRecord.md +38 -0
  231. data/docs/RwdSourcesResponse.md +58 -0
  232. data/docs/RwdSourcesRow.md +280 -0
  233. data/docs/RwdStudiesApi.md +473 -0
  234. data/docs/RwdStudiesRecord.md +38 -0
  235. data/docs/RwdStudiesResponse.md +58 -0
  236. data/docs/RwdStudiesRow.md +180 -0
  237. data/docs/RwdStudyConditionsResponse.md +58 -0
  238. data/docs/RwdStudyConditionsRow.md +54 -0
  239. data/docs/RwdStudyDataSourcesResponse.md +58 -0
  240. data/docs/RwdStudyDataSourcesRow.md +54 -0
  241. data/docs/RwdStudyDrugsResponse.md +58 -0
  242. data/docs/RwdStudyDrugsRow.md +50 -0
  243. data/docs/RwdStudyMilestonesResponse.md +58 -0
  244. data/docs/RwdStudyMilestonesRow.md +54 -0
  245. data/docs/RwdWithheldFieldsResponse.md +58 -0
  246. data/docs/RwdWithheldFieldsRow.md +36 -0
  247. data/docs/SecPdufaDatesResponse.md +58 -0
  248. data/docs/SecPdufaDatesRow.md +64 -0
  249. data/docs/SiteBedsYearlyResponse.md +3 -3
  250. data/docs/SiteCroTrialsResponse.md +3 -3
  251. data/docs/SiteHospitalsResponse.md +3 -3
  252. data/docs/SiteInvestigatorsResponse.md +3 -3
  253. data/docs/SiteTrialConditionsResponse.md +3 -3
  254. data/docs/SiteTrialDrugsResponse.md +3 -3
  255. data/docs/SiteTrialsResponse.md +3 -3
  256. data/docs/SitesRecord.md +2 -2
  257. data/docs/SitesResponse.md +3 -3
  258. data/docs/SponsorRecruitmentByPhaseResponse.md +3 -3
  259. data/docs/SponsorRecruitmentDurationResponse.md +3 -3
  260. data/docs/SponsorTrialStartForecastResponse.md +3 -3
  261. data/docs/SponsorTrialsResponse.md +3 -3
  262. data/docs/SponsorTrialsRow.md +1 -1
  263. data/docs/SupplierCapabilityEsgResponse.md +58 -0
  264. data/docs/SupplierCapabilityEsgRow.md +64 -0
  265. data/docs/SupplierServicesResponse.md +58 -0
  266. data/docs/SupplierServicesRow.md +30 -0
  267. data/docs/SupplierSitesResponse.md +58 -0
  268. data/docs/SupplierSitesRow.md +42 -0
  269. data/docs/SuppliersApi.md +313 -0
  270. data/docs/SuppliersRecord.md +38 -0
  271. data/docs/SuppliersResponse.md +58 -0
  272. data/docs/SuppliersRow.md +76 -0
  273. data/docs/TargetAssociationsResponse.md +58 -0
  274. data/docs/TargetAssociationsRow.md +26 -0
  275. data/docs/TargetCrowdingResponse.md +58 -0
  276. data/docs/TargetCrowdingRow.md +30 -0
  277. data/docs/TargetDrugsResponse.md +58 -0
  278. data/docs/TargetDrugsRow.md +38 -0
  279. data/docs/TargetEvidenceResponse.md +58 -0
  280. data/docs/TargetEvidenceRow.md +52 -0
  281. data/docs/TargetPatentMentionsResponse.md +58 -0
  282. data/docs/TargetPatentMentionsRow.md +34 -0
  283. data/docs/TargetProgramsResponse.md +58 -0
  284. data/docs/TargetProgramsRow.md +58 -0
  285. data/docs/TargetPublicationsResponse.md +58 -0
  286. data/docs/TargetPublicationsRow.md +32 -0
  287. data/docs/TargetRegulatoryPrecedentResponse.md +58 -0
  288. data/docs/TargetRegulatoryPrecedentRow.md +38 -0
  289. data/docs/TargetTrialsResponse.md +58 -0
  290. data/docs/TargetTrialsRow.md +46 -0
  291. data/docs/TargetsApi.md +1033 -0
  292. data/docs/TargetsRecord.md +38 -0
  293. data/docs/TargetsResponse.md +58 -0
  294. data/docs/TargetsRow.md +68 -0
  295. data/docs/TrialAdverseEventsResponse.md +3 -3
  296. data/docs/TrialChangesResponse.md +3 -3
  297. data/docs/TrialChangesRow.md +5 -1
  298. data/docs/TrialDeliveryResponse.md +3 -3
  299. data/docs/TrialDemographicsResponse.md +3 -3
  300. data/docs/TrialDrugClassesResponse.md +58 -0
  301. data/docs/TrialDrugClassesRow.md +28 -0
  302. data/docs/TrialDrugsResponse.md +3 -3
  303. data/docs/TrialEnrollmentHistoryResponse.md +3 -3
  304. data/docs/TrialEnrollmentRateResponse.md +3 -3
  305. data/docs/TrialExtractedEndpointsResponse.md +3 -3
  306. data/docs/TrialKolsResponse.md +58 -0
  307. data/docs/TrialKolsRow.md +32 -0
  308. data/docs/TrialOutcomeMeasuresResponse.md +3 -3
  309. data/docs/TrialResearchPaymentsResponse.md +58 -0
  310. data/docs/TrialResearchPaymentsRow.md +44 -0
  311. data/docs/TrialSiteHistoryResponse.md +58 -0
  312. data/docs/TrialSiteHistoryRow.md +50 -0
  313. data/docs/TrialSitesResponse.md +3 -3
  314. data/docs/TrialsApi.md +400 -0
  315. data/docs/TrialsRecord.md +2 -2
  316. data/docs/TrialsResponse.md +3 -3
  317. data/docs/TrialsRow.md +9 -1
  318. data/docs/UnmatchedProductRevenueResponse.md +58 -0
  319. data/docs/UnmatchedProductRevenueRow.md +80 -0
  320. data/docs/UntitledLettersResponse.md +58 -0
  321. data/docs/UntitledLettersRow.md +44 -0
  322. data/docs/WarningLettersResponse.md +58 -0
  323. data/docs/WarningLettersRow.md +50 -0
  324. data/lib/pharmaobservatory/api/biomarkers_api.rb +168 -0
  325. data/lib/pharmaobservatory/api/companies_api.rb +2164 -162
  326. data/lib/pharmaobservatory/api/conditions_api.rb +588 -0
  327. data/lib/pharmaobservatory/api/drugs_api.rb +2261 -0
  328. data/lib/pharmaobservatory/api/hospitals_api.rb +413 -0
  329. data/lib/pharmaobservatory/api/investors_api.rb +665 -0
  330. data/lib/pharmaobservatory/api/legal_entities_api.rb +1670 -158
  331. data/lib/pharmaobservatory/api/managers_api.rb +245 -0
  332. data/lib/pharmaobservatory/api/rare_diseases_api.rb +1421 -0
  333. data/lib/pharmaobservatory/api/rwd_registers_api.rb +329 -0
  334. data/lib/pharmaobservatory/api/rwd_sources_api.rb +749 -0
  335. data/lib/pharmaobservatory/api/rwd_studies_api.rb +497 -0
  336. data/lib/pharmaobservatory/api/suppliers_api.rb +329 -0
  337. data/lib/pharmaobservatory/api/targets_api.rb +1085 -0
  338. data/lib/pharmaobservatory/api/trials_api.rb +420 -0
  339. data/lib/pharmaobservatory/models/biomarker_assay_evidence_response.rb +478 -0
  340. data/lib/pharmaobservatory/models/{biomarker_cdx_assertions_response_build.rb → biomarker_assay_evidence_response_build.rb} +3 -3
  341. data/lib/pharmaobservatory/models/{biomarker_cdx_assertions_response_freshness.rb → biomarker_assay_evidence_response_freshness.rb} +3 -3
  342. data/lib/pharmaobservatory/models/{biomarker_cdx_assertions_response_scope.rb → biomarker_assay_evidence_response_scope.rb} +3 -3
  343. data/lib/pharmaobservatory/models/biomarker_assay_evidence_row.rb +506 -0
  344. data/lib/pharmaobservatory/models/biomarker_assay_whitespace_response.rb +478 -0
  345. data/lib/pharmaobservatory/models/biomarker_assay_whitespace_row.rb +499 -0
  346. data/lib/pharmaobservatory/models/biomarker_bqp_assertions_response.rb +3 -3
  347. data/lib/pharmaobservatory/models/biomarker_cdx_assertions_response.rb +3 -3
  348. data/lib/pharmaobservatory/models/biomarker_evidence_response.rb +3 -3
  349. data/lib/pharmaobservatory/models/biomarker_literature_response.rb +3 -3
  350. data/lib/pharmaobservatory/models/biomarker_publishing_companies_response.rb +3 -3
  351. data/lib/pharmaobservatory/models/biomarker_publishing_companies_row.rb +49 -5
  352. data/lib/pharmaobservatory/models/biomarker_relations_response.rb +3 -3
  353. data/lib/pharmaobservatory/models/biomarker_sample_coverage_response.rb +3 -3
  354. data/lib/pharmaobservatory/models/biomarker_sample_prevalence_response.rb +3 -3
  355. data/lib/pharmaobservatory/models/biomarker_validation_response.rb +3 -3
  356. data/lib/pharmaobservatory/models/biomarker_variant_mentions_response.rb +3 -3
  357. data/lib/pharmaobservatory/models/biomarkers_record.rb +2 -2
  358. data/lib/pharmaobservatory/models/biomarkers_response.rb +3 -3
  359. data/lib/pharmaobservatory/models/biomarkers_row.rb +12 -1
  360. data/lib/pharmaobservatory/models/brand_companies_response.rb +478 -0
  361. data/lib/pharmaobservatory/models/brand_companies_row.rb +401 -0
  362. data/lib/pharmaobservatory/models/brand_revenue_response.rb +478 -0
  363. data/lib/pharmaobservatory/models/brand_revenue_row.rb +454 -0
  364. data/lib/pharmaobservatory/models/catalysts_response.rb +478 -0
  365. data/lib/pharmaobservatory/models/catalysts_row.rb +623 -0
  366. data/lib/pharmaobservatory/models/cell_lines_record.rb +2 -2
  367. data/lib/pharmaobservatory/models/cell_lines_response.rb +3 -3
  368. data/lib/pharmaobservatory/models/clia_certificates_response.rb +478 -0
  369. data/lib/pharmaobservatory/models/clia_certificates_row.rb +568 -0
  370. data/lib/pharmaobservatory/models/companies_record.rb +2 -2
  371. data/lib/pharmaobservatory/models/companies_record_attributes.rb +13 -4
  372. data/lib/pharmaobservatory/models/companies_response.rb +3 -3
  373. data/lib/pharmaobservatory/models/companies_row.rb +1 -1
  374. data/lib/pharmaobservatory/models/company_assets_response.rb +3 -3
  375. data/lib/pharmaobservatory/models/company_funding_events_response.rb +3 -3
  376. data/lib/pharmaobservatory/models/company_funding_events_row.rb +13 -2
  377. data/lib/pharmaobservatory/models/company_funding_summary_response.rb +3 -3
  378. data/lib/pharmaobservatory/models/company_members_response.rb +3 -3
  379. data/lib/pharmaobservatory/models/company_programs_response.rb +3 -3
  380. data/lib/pharmaobservatory/models/company_targets_response.rb +3 -3
  381. data/lib/pharmaobservatory/models/company_targets_row.rb +27 -5
  382. data/lib/pharmaobservatory/models/company_trial_geography_response.rb +478 -0
  383. data/lib/pharmaobservatory/models/company_trial_geography_row.rb +410 -0
  384. data/lib/pharmaobservatory/models/company_trial_sites_response.rb +478 -0
  385. data/lib/pharmaobservatory/models/company_trial_sites_row.rb +410 -0
  386. data/lib/pharmaobservatory/models/condition_adverse_events_response.rb +3 -3
  387. data/lib/pharmaobservatory/models/condition_burden_response.rb +3 -3
  388. data/lib/pharmaobservatory/models/condition_delivery_response.rb +3 -3
  389. data/lib/pharmaobservatory/models/condition_drugs_response.rb +3 -3
  390. data/lib/pharmaobservatory/models/condition_prevalence_response.rb +3 -3
  391. data/lib/pharmaobservatory/models/condition_prevalence_row.rb +1 -1
  392. data/lib/pharmaobservatory/models/condition_publications_response.rb +3 -3
  393. data/lib/pharmaobservatory/models/condition_recruitment_by_phase_response.rb +478 -0
  394. data/lib/pharmaobservatory/models/condition_recruitment_by_phase_row.rb +399 -0
  395. data/lib/pharmaobservatory/models/condition_recruitment_duration_response.rb +478 -0
  396. data/lib/pharmaobservatory/models/condition_recruitment_duration_row.rb +597 -0
  397. data/lib/pharmaobservatory/models/condition_sites_response.rb +3 -3
  398. data/lib/pharmaobservatory/models/condition_trial_start_forecast_response.rb +478 -0
  399. data/lib/pharmaobservatory/models/condition_trial_start_forecast_row.rb +509 -0
  400. data/lib/pharmaobservatory/models/condition_trials_response.rb +3 -3
  401. data/lib/pharmaobservatory/models/condition_trials_row.rb +1 -1
  402. data/lib/pharmaobservatory/models/conditions_record.rb +2 -2
  403. data/lib/pharmaobservatory/models/conditions_record_attributes.rb +13 -4
  404. data/lib/pharmaobservatory/models/conditions_response.rb +3 -3
  405. data/lib/pharmaobservatory/models/cro_footprint_response.rb +478 -0
  406. data/lib/pharmaobservatory/models/cro_footprint_row.rb +311 -0
  407. data/lib/pharmaobservatory/models/cro_trials_response.rb +478 -0
  408. data/lib/pharmaobservatory/models/cro_trials_row.rb +381 -0
  409. data/lib/pharmaobservatory/models/debarments_response.rb +478 -0
  410. data/lib/pharmaobservatory/models/debarments_row.rb +366 -0
  411. data/lib/pharmaobservatory/models/drug_approvals_response.rb +478 -0
  412. data/lib/pharmaobservatory/models/drug_approvals_row.rb +278 -0
  413. data/lib/pharmaobservatory/models/drug_asp_codes_response.rb +478 -0
  414. data/lib/pharmaobservatory/models/drug_asp_codes_row.rb +278 -0
  415. data/lib/pharmaobservatory/models/drug_brands_response.rb +478 -0
  416. data/lib/pharmaobservatory/models/drug_brands_row.rb +454 -0
  417. data/lib/pharmaobservatory/models/drug_combinations_response.rb +478 -0
  418. data/lib/pharmaobservatory/models/drug_combinations_row.rb +300 -0
  419. data/lib/pharmaobservatory/models/drug_declared_patents_response.rb +478 -0
  420. data/lib/pharmaobservatory/models/drug_declared_patents_row.rb +447 -0
  421. data/lib/pharmaobservatory/models/drug_label_safety_response.rb +478 -0
  422. data/lib/pharmaobservatory/models/drug_label_safety_row.rb +300 -0
  423. data/lib/pharmaobservatory/models/drug_medicare_spend_response.rb +478 -0
  424. data/lib/pharmaobservatory/models/drug_medicare_spend_row.rb +280 -0
  425. data/lib/pharmaobservatory/models/drug_patent_cliff_response.rb +3 -3
  426. data/lib/pharmaobservatory/models/drug_patent_cliff_row.rb +13 -2
  427. data/lib/pharmaobservatory/models/drug_patent_mentions_response.rb +478 -0
  428. data/lib/pharmaobservatory/models/drug_patent_mentions_row.rb +278 -0
  429. data/lib/pharmaobservatory/models/drug_patent_owners_response.rb +478 -0
  430. data/lib/pharmaobservatory/models/drug_patent_owners_row.rb +357 -0
  431. data/lib/pharmaobservatory/models/drug_pricing_response.rb +478 -0
  432. data/lib/pharmaobservatory/models/drug_pricing_row.rb +300 -0
  433. data/lib/pharmaobservatory/models/drug_recalls_response.rb +478 -0
  434. data/lib/pharmaobservatory/models/drug_recalls_row.rb +311 -0
  435. data/lib/pharmaobservatory/models/drug_regulatory_response.rb +478 -0
  436. data/lib/pharmaobservatory/models/drug_regulatory_row.rb +333 -0
  437. data/lib/pharmaobservatory/models/drug_sites_response.rb +478 -0
  438. data/lib/pharmaobservatory/models/drug_sites_row.rb +278 -0
  439. data/lib/pharmaobservatory/models/drug_targets_response.rb +478 -0
  440. data/lib/pharmaobservatory/models/drug_targets_row.rb +324 -0
  441. data/lib/pharmaobservatory/models/drug_trial_conditions_response.rb +478 -0
  442. data/lib/pharmaobservatory/models/drug_trial_conditions_row.rb +289 -0
  443. data/lib/pharmaobservatory/models/drug_trials_response.rb +478 -0
  444. data/lib/pharmaobservatory/models/drug_trials_row.rb +445 -0
  445. data/lib/pharmaobservatory/models/drug_variants_response.rb +478 -0
  446. data/lib/pharmaobservatory/models/drug_variants_row.rb +333 -0
  447. data/lib/pharmaobservatory/models/drugs_record.rb +385 -0
  448. data/lib/pharmaobservatory/models/drugs_record_attributes.rb +229 -0
  449. data/lib/pharmaobservatory/models/drugs_response.rb +478 -0
  450. data/lib/pharmaobservatory/models/drugs_row.rb +581 -0
  451. data/lib/pharmaobservatory/models/enforcement_events_response.rb +478 -0
  452. data/lib/pharmaobservatory/models/enforcement_events_row.rb +476 -0
  453. data/lib/pharmaobservatory/models/gxp_facilities_response.rb +478 -0
  454. data/lib/pharmaobservatory/models/gxp_facilities_row.rb +968 -0
  455. data/lib/pharmaobservatory/models/hospital_beds_yearly_response.rb +478 -0
  456. data/lib/pharmaobservatory/models/hospital_beds_yearly_row.rb +278 -0
  457. data/lib/pharmaobservatory/models/hospital_facility_changes_response.rb +478 -0
  458. data/lib/pharmaobservatory/models/hospital_facility_changes_row.rb +289 -0
  459. data/lib/pharmaobservatory/models/hospitals_record.rb +385 -0
  460. data/lib/pharmaobservatory/models/hospitals_response.rb +478 -0
  461. data/lib/pharmaobservatory/models/hospitals_row.rb +344 -0
  462. data/lib/pharmaobservatory/models/import_refusals_response.rb +478 -0
  463. data/lib/pharmaobservatory/models/import_refusals_row.rb +454 -0
  464. data/lib/pharmaobservatory/models/inspection_findings_response.rb +478 -0
  465. data/lib/pharmaobservatory/models/inspection_findings_row.rb +388 -0
  466. data/lib/pharmaobservatory/models/inspections_response.rb +478 -0
  467. data/lib/pharmaobservatory/models/inspections_row.rb +454 -0
  468. data/lib/pharmaobservatory/models/institutional_holdings_response.rb +3 -3
  469. data/lib/pharmaobservatory/models/institutional_holdings_row.rb +35 -2
  470. data/lib/pharmaobservatory/models/institutional_quarter_totals_response.rb +478 -0
  471. data/lib/pharmaobservatory/models/institutional_quarter_totals_row.rb +443 -0
  472. data/lib/pharmaobservatory/models/investor_funds_response.rb +478 -0
  473. data/lib/pharmaobservatory/models/investor_funds_row.rb +256 -0
  474. data/lib/pharmaobservatory/models/investor_portfolio_response.rb +478 -0
  475. data/lib/pharmaobservatory/models/investor_portfolio_row.rb +357 -0
  476. data/lib/pharmaobservatory/models/investor_private_funds_response.rb +478 -0
  477. data/lib/pharmaobservatory/models/investor_private_funds_row.rb +366 -0
  478. data/lib/pharmaobservatory/models/investors_record.rb +385 -0
  479. data/lib/pharmaobservatory/models/investors_response.rb +478 -0
  480. data/lib/pharmaobservatory/models/investors_row.rb +421 -0
  481. data/lib/pharmaobservatory/models/legal_entities_record.rb +2 -2
  482. data/lib/pharmaobservatory/models/legal_entities_record_attributes.rb +10 -1
  483. data/lib/pharmaobservatory/models/legal_entities_response.rb +3 -3
  484. data/lib/pharmaobservatory/models/legal_entities_row.rb +1 -1
  485. data/lib/pharmaobservatory/models/managers_record.rb +385 -0
  486. data/lib/pharmaobservatory/models/managers_response.rb +478 -0
  487. data/lib/pharmaobservatory/models/managers_row.rb +377 -0
  488. data/lib/pharmaobservatory/models/org_disclosures_response.rb +478 -0
  489. data/lib/pharmaobservatory/models/org_disclosures_row.rb +432 -0
  490. data/lib/pharmaobservatory/models/org_relationships_response.rb +478 -0
  491. data/lib/pharmaobservatory/models/org_relationships_row.rb +498 -0
  492. data/lib/pharmaobservatory/models/ownership_percentages_response.rb +478 -0
  493. data/lib/pharmaobservatory/models/ownership_percentages_row.rb +531 -0
  494. data/lib/pharmaobservatory/models/ownership_positions_response.rb +3 -3
  495. data/lib/pharmaobservatory/models/ownership_positions_row.rb +26 -15
  496. data/lib/pharmaobservatory/models/pdufa_dates_response.rb +3 -3
  497. data/lib/pharmaobservatory/models/pdufa_dates_row.rb +1 -1
  498. data/lib/pharmaobservatory/models/program_licensing_candidates_response.rb +478 -0
  499. data/lib/pharmaobservatory/models/program_licensing_candidates_row.rb +445 -0
  500. data/lib/pharmaobservatory/models/programs_response.rb +478 -0
  501. data/lib/pharmaobservatory/models/programs_row.rb +377 -0
  502. data/lib/pharmaobservatory/models/rare_disease_genes_response.rb +478 -0
  503. data/lib/pharmaobservatory/models/rare_disease_genes_row.rb +399 -0
  504. data/lib/pharmaobservatory/models/rare_disease_hierarchy_response.rb +478 -0
  505. data/lib/pharmaobservatory/models/rare_disease_hierarchy_row.rb +344 -0
  506. data/lib/pharmaobservatory/models/rare_disease_investigator_coverage_response.rb +478 -0
  507. data/lib/pharmaobservatory/models/rare_disease_investigator_coverage_row.rb +333 -0
  508. data/lib/pharmaobservatory/models/rare_disease_investigators_response.rb +478 -0
  509. data/lib/pharmaobservatory/models/rare_disease_investigators_row.rb +436 -0
  510. data/lib/pharmaobservatory/models/rare_disease_mappings_response.rb +478 -0
  511. data/lib/pharmaobservatory/models/rare_disease_mappings_row.rb +366 -0
  512. data/lib/pharmaobservatory/models/rare_disease_organizations_response.rb +478 -0
  513. data/lib/pharmaobservatory/models/rare_disease_organizations_row.rb +454 -0
  514. data/lib/pharmaobservatory/models/rare_disease_prevalence_response.rb +478 -0
  515. data/lib/pharmaobservatory/models/rare_disease_prevalence_row.rb +465 -0
  516. data/lib/pharmaobservatory/models/rare_disease_rarity_evidence_response.rb +478 -0
  517. data/lib/pharmaobservatory/models/rare_disease_rarity_evidence_row.rb +322 -0
  518. data/lib/pharmaobservatory/models/rare_disease_rarity_response.rb +478 -0
  519. data/lib/pharmaobservatory/models/rare_disease_rarity_row.rb +421 -0
  520. data/lib/pharmaobservatory/models/rare_disease_replacements_response.rb +478 -0
  521. data/lib/pharmaobservatory/models/rare_disease_replacements_row.rb +344 -0
  522. data/lib/pharmaobservatory/models/rare_disease_site_coverage_response.rb +478 -0
  523. data/lib/pharmaobservatory/models/rare_disease_site_coverage_row.rb +421 -0
  524. data/lib/pharmaobservatory/models/rare_disease_sponsors_response.rb +478 -0
  525. data/lib/pharmaobservatory/models/rare_disease_sponsors_row.rb +575 -0
  526. data/lib/pharmaobservatory/models/rare_disease_trial_coverage_response.rb +478 -0
  527. data/lib/pharmaobservatory/models/rare_disease_trial_coverage_row.rb +449 -0
  528. data/lib/pharmaobservatory/models/rare_disease_trial_sites_response.rb +478 -0
  529. data/lib/pharmaobservatory/models/rare_disease_trial_sites_row.rb +412 -0
  530. data/lib/pharmaobservatory/models/rare_disease_trials_response.rb +478 -0
  531. data/lib/pharmaobservatory/models/rare_disease_trials_row.rb +623 -0
  532. data/lib/pharmaobservatory/models/rare_diseases_record.rb +385 -0
  533. data/lib/pharmaobservatory/models/rare_diseases_record_attributes.rb +238 -0
  534. data/lib/pharmaobservatory/models/rare_diseases_response.rb +478 -0
  535. data/lib/pharmaobservatory/models/rare_diseases_row.rb +500 -0
  536. data/lib/pharmaobservatory/models/recalls_response.rb +478 -0
  537. data/lib/pharmaobservatory/models/recalls_row.rb +421 -0
  538. data/lib/pharmaobservatory/models/rwd_coverage_response.rb +478 -0
  539. data/lib/pharmaobservatory/models/rwd_coverage_row.rb +410 -0
  540. data/lib/pharmaobservatory/models/rwd_register_provenance_response.rb +478 -0
  541. data/lib/pharmaobservatory/models/rwd_register_provenance_row.rb +531 -0
  542. data/lib/pharmaobservatory/models/rwd_registers_record.rb +385 -0
  543. data/lib/pharmaobservatory/models/rwd_source_age_bands_response.rb +478 -0
  544. data/lib/pharmaobservatory/models/rwd_source_age_bands_row.rb +344 -0
  545. data/lib/pharmaobservatory/models/rwd_source_conditions_response.rb +478 -0
  546. data/lib/pharmaobservatory/models/rwd_source_conditions_row.rb +502 -0
  547. data/lib/pharmaobservatory/models/rwd_source_etl_mappings_response.rb +478 -0
  548. data/lib/pharmaobservatory/models/rwd_source_etl_mappings_row.rb +366 -0
  549. data/lib/pharmaobservatory/models/rwd_source_linkages_response.rb +478 -0
  550. data/lib/pharmaobservatory/models/rwd_source_linkages_row.rb +476 -0
  551. data/lib/pharmaobservatory/models/rwd_source_types_response.rb +478 -0
  552. data/lib/pharmaobservatory/models/rwd_source_types_row.rb +311 -0
  553. data/lib/pharmaobservatory/models/rwd_source_vocabularies_response.rb +478 -0
  554. data/lib/pharmaobservatory/models/rwd_source_vocabularies_row.rb +355 -0
  555. data/lib/pharmaobservatory/models/rwd_sources_record.rb +385 -0
  556. data/lib/pharmaobservatory/models/rwd_sources_response.rb +478 -0
  557. data/lib/pharmaobservatory/models/rwd_sources_row.rb +1674 -0
  558. data/lib/pharmaobservatory/models/rwd_studies_record.rb +385 -0
  559. data/lib/pharmaobservatory/models/rwd_studies_response.rb +478 -0
  560. data/lib/pharmaobservatory/models/rwd_studies_row.rb +1138 -0
  561. data/lib/pharmaobservatory/models/rwd_study_conditions_response.rb +478 -0
  562. data/lib/pharmaobservatory/models/rwd_study_conditions_row.rb +421 -0
  563. data/lib/pharmaobservatory/models/rwd_study_data_sources_response.rb +478 -0
  564. data/lib/pharmaobservatory/models/rwd_study_data_sources_row.rb +423 -0
  565. data/lib/pharmaobservatory/models/rwd_study_drugs_response.rb +478 -0
  566. data/lib/pharmaobservatory/models/rwd_study_drugs_row.rb +401 -0
  567. data/lib/pharmaobservatory/models/rwd_study_milestones_response.rb +478 -0
  568. data/lib/pharmaobservatory/models/rwd_study_milestones_row.rb +421 -0
  569. data/lib/pharmaobservatory/models/rwd_withheld_fields_response.rb +478 -0
  570. data/lib/pharmaobservatory/models/rwd_withheld_fields_row.rb +322 -0
  571. data/lib/pharmaobservatory/models/sec_pdufa_dates_response.rb +478 -0
  572. data/lib/pharmaobservatory/models/sec_pdufa_dates_row.rb +476 -0
  573. data/lib/pharmaobservatory/models/site_beds_yearly_response.rb +3 -3
  574. data/lib/pharmaobservatory/models/site_cro_trials_response.rb +3 -3
  575. data/lib/pharmaobservatory/models/site_hospitals_response.rb +3 -3
  576. data/lib/pharmaobservatory/models/site_investigators_response.rb +3 -3
  577. data/lib/pharmaobservatory/models/site_trial_conditions_response.rb +3 -3
  578. data/lib/pharmaobservatory/models/site_trial_drugs_response.rb +3 -3
  579. data/lib/pharmaobservatory/models/site_trials_response.rb +3 -3
  580. data/lib/pharmaobservatory/models/sites_record.rb +2 -2
  581. data/lib/pharmaobservatory/models/sites_response.rb +3 -3
  582. data/lib/pharmaobservatory/models/sponsor_recruitment_by_phase_response.rb +3 -3
  583. data/lib/pharmaobservatory/models/sponsor_recruitment_duration_response.rb +3 -3
  584. data/lib/pharmaobservatory/models/sponsor_trial_start_forecast_response.rb +3 -3
  585. data/lib/pharmaobservatory/models/sponsor_trials_response.rb +3 -3
  586. data/lib/pharmaobservatory/models/sponsor_trials_row.rb +1 -1
  587. data/lib/pharmaobservatory/models/supplier_capability_esg_response.rb +478 -0
  588. data/lib/pharmaobservatory/models/supplier_capability_esg_row.rb +480 -0
  589. data/lib/pharmaobservatory/models/supplier_services_response.rb +478 -0
  590. data/lib/pharmaobservatory/models/supplier_services_row.rb +289 -0
  591. data/lib/pharmaobservatory/models/supplier_sites_response.rb +478 -0
  592. data/lib/pharmaobservatory/models/supplier_sites_row.rb +357 -0
  593. data/lib/pharmaobservatory/models/suppliers_record.rb +385 -0
  594. data/lib/pharmaobservatory/models/suppliers_response.rb +478 -0
  595. data/lib/pharmaobservatory/models/suppliers_row.rb +544 -0
  596. data/lib/pharmaobservatory/models/target_associations_response.rb +478 -0
  597. data/lib/pharmaobservatory/models/target_associations_row.rb +267 -0
  598. data/lib/pharmaobservatory/models/target_crowding_response.rb +478 -0
  599. data/lib/pharmaobservatory/models/target_crowding_row.rb +289 -0
  600. data/lib/pharmaobservatory/models/target_drugs_response.rb +478 -0
  601. data/lib/pharmaobservatory/models/target_drugs_row.rb +335 -0
  602. data/lib/pharmaobservatory/models/target_evidence_response.rb +478 -0
  603. data/lib/pharmaobservatory/models/target_evidence_row.rb +410 -0
  604. data/lib/pharmaobservatory/models/target_patent_mentions_response.rb +478 -0
  605. data/lib/pharmaobservatory/models/target_patent_mentions_row.rb +311 -0
  606. data/lib/pharmaobservatory/models/target_programs_response.rb +478 -0
  607. data/lib/pharmaobservatory/models/target_programs_row.rb +447 -0
  608. data/lib/pharmaobservatory/models/target_publications_response.rb +478 -0
  609. data/lib/pharmaobservatory/models/target_publications_row.rb +300 -0
  610. data/lib/pharmaobservatory/models/target_regulatory_precedent_response.rb +478 -0
  611. data/lib/pharmaobservatory/models/target_regulatory_precedent_row.rb +333 -0
  612. data/lib/pharmaobservatory/models/target_trials_response.rb +478 -0
  613. data/lib/pharmaobservatory/models/target_trials_row.rb +377 -0
  614. data/lib/pharmaobservatory/models/targets_record.rb +385 -0
  615. data/lib/pharmaobservatory/models/targets_response.rb +478 -0
  616. data/lib/pharmaobservatory/models/targets_row.rb +498 -0
  617. data/lib/pharmaobservatory/models/trial_adverse_events_response.rb +3 -3
  618. data/lib/pharmaobservatory/models/trial_changes_response.rb +3 -3
  619. data/lib/pharmaobservatory/models/trial_changes_row.rb +24 -2
  620. data/lib/pharmaobservatory/models/trial_delivery_response.rb +3 -3
  621. data/lib/pharmaobservatory/models/trial_demographics_response.rb +3 -3
  622. data/lib/pharmaobservatory/models/trial_drug_classes_response.rb +478 -0
  623. data/lib/pharmaobservatory/models/trial_drug_classes_row.rb +278 -0
  624. data/lib/pharmaobservatory/models/trial_drugs_response.rb +3 -3
  625. data/lib/pharmaobservatory/models/trial_enrollment_history_response.rb +3 -3
  626. data/lib/pharmaobservatory/models/trial_enrollment_rate_response.rb +3 -3
  627. data/lib/pharmaobservatory/models/trial_extracted_endpoints_response.rb +3 -3
  628. data/lib/pharmaobservatory/models/trial_kols_response.rb +478 -0
  629. data/lib/pharmaobservatory/models/trial_kols_row.rb +302 -0
  630. data/lib/pharmaobservatory/models/trial_outcome_measures_response.rb +3 -3
  631. data/lib/pharmaobservatory/models/trial_research_payments_response.rb +478 -0
  632. data/lib/pharmaobservatory/models/trial_research_payments_row.rb +366 -0
  633. data/lib/pharmaobservatory/models/trial_site_history_response.rb +478 -0
  634. data/lib/pharmaobservatory/models/trial_site_history_row.rb +401 -0
  635. data/lib/pharmaobservatory/models/trial_sites_response.rb +3 -3
  636. data/lib/pharmaobservatory/models/trials_record.rb +2 -2
  637. data/lib/pharmaobservatory/models/trials_response.rb +3 -3
  638. data/lib/pharmaobservatory/models/trials_row.rb +47 -3
  639. data/lib/pharmaobservatory/models/unmatched_product_revenue_response.rb +478 -0
  640. data/lib/pharmaobservatory/models/unmatched_product_revenue_row.rb +564 -0
  641. data/lib/pharmaobservatory/models/untitled_letters_response.rb +478 -0
  642. data/lib/pharmaobservatory/models/untitled_letters_row.rb +366 -0
  643. data/lib/pharmaobservatory/models/warning_letters_response.rb +478 -0
  644. data/lib/pharmaobservatory/models/warning_letters_row.rb +399 -0
  645. data/lib/pharmaobservatory/version.rb +1 -1
  646. data/lib/pharmaobservatory.rb +235 -3
  647. metadata +472 -8
@@ -0,0 +1,68 @@
1
+ # PharmaObservatory::OrgRelationshipsRow
2
+
3
+ ## Properties
4
+
5
+ | Name | Type | Description | Notes |
6
+ | ---- | ---- | ----------- | ----- |
7
+ | **subject_org_id** | **String** | Legal-entity level: the subject's organization record. | [optional] |
8
+ | **subject_name** | **String** | The organization's name as filed. | [optional] |
9
+ | **subject_company_id** | **String** | Company level: the subject's company (null when unresolved). | [optional] |
10
+ | **subject_company_name** | **String** | Display name of the subject's company. | [optional] |
11
+ | **subject_group_id** | **String** | Group level: the subject's current ultimate parent; a root's group is itself. | [optional] |
12
+ | **subject_group_name** | **String** | Display name of the subject's group. | [optional] |
13
+ | **object_org_id** | **String** | Legal-entity level: the object's organization record. | [optional] |
14
+ | **object_name** | **String** | The organization's name as filed. | [optional] |
15
+ | **object_company_id** | **String** | Company level: the object's company (null when unresolved). | [optional] |
16
+ | **object_company_name** | **String** | Display name of the object's company. | [optional] |
17
+ | **object_group_id** | **String** | Group level: the object's current ultimate parent; a root's group is itself. | [optional] |
18
+ | **object_group_name** | **String** | Display name of the object's group. | [optional] |
19
+ | **predicate** | **String** | The directed relationship from subject to object: parent_of and ultimate_parent_of (corporate ownership, the subject is the parent), linked_charity_of (a charity linked to the main charity), uses_vendor (a sponsor and the contract research organization inferred for its trials), co_sponsors_trial_with (two sponsors of one trial), project_partner_of and awards_to (UK research grants). | [optional] |
20
+ | **edge_family** | **String** | The family of the predicate: corporate_structure (parent_of, ultimate_parent_of, linked_charity_of), contract_vendor (uses_vendor), co_sponsorship (co_sponsors_trial_with) or research_funding (project_partner_of, awards_to). | [optional] |
21
+ | **edge_scope** | **String** | general for an edge from a source that covers organizations at large (GLEIF, Charity Commission, the contract research organization (CRO) inference); rare_disease_scoped for an edge from a source read only for organizations in the rare-disease evidence set (ROR, co-sponsorship, UK research grants). A rare_disease_scoped edge is a true edge and an incomplete picture: an organization with none of them has not been shown to have none. | [optional] |
22
+ | **source_key** | **String** | The source that asserted the edge: gleif (Global Legal Entity Identifier Foundation Golden Copy), charity_commission, aact_cro_inference (inferred from ClinicalTrials.gov filings against a curated CRO list), ror (Research Organization Registry), aact (ClinicalTrials.gov) or ukri_gtr (UK Research and Innovation Gateway to Research). | [optional] |
23
+ | **evidence_type** | **String** | The kind of evidence behind the edge: registry (a register entry), trial, project or grant. | [optional] |
24
+ | **authority_class** | **String** | authoritative when the source itself filed the relationship; derived when the edge is an inference (the CRO edge is a curated-list name match, not a filing). | [optional] |
25
+ | **evidence_count** | **Integer** | The source records behind the edge. Counted within one source, so it does not add across sources. | [optional] |
26
+ | **context_count** | **Integer** | Distinct source record contexts among them (for example distinct trials). | [optional] |
27
+ | **confidence** | **Float** | The highest confidence among the edge's records, 0 to 1, where the source states one. Null for sources that state none. A GLEIF ownership-resolution score and a CRO name-match score are different measures; do not compare them. | [optional] |
28
+ | **first_observed_at** | **Time** | When the earliest of the edge's records was observed in the source. | [optional] |
29
+ | **last_observed_at** | **Time** | When the latest of the edge's records was observed in the source. | [optional] |
30
+ | **license_name** | **String** | The licence of the source behind the edge. | [optional] |
31
+ | **attribution** | **String** | The credit line the source requires for the edge. Show it wherever the edge is shown: the Charity Commission and UK Research and Innovation edges require it under the Open Government Licence v3.0. | [optional] |
32
+ | **restriction_tier** | **String** | The tier vocabulary is none or licensable. Every row here is none: every source behind these edges is open, and a test on the source assertions reports any restricted source that is ever added. | [optional] |
33
+
34
+ ## Example
35
+
36
+ ```ruby
37
+ require 'pharmaobservatory'
38
+
39
+ instance = PharmaObservatory::OrgRelationshipsRow.new(
40
+ subject_org_id: null,
41
+ subject_name: null,
42
+ subject_company_id: null,
43
+ subject_company_name: null,
44
+ subject_group_id: null,
45
+ subject_group_name: null,
46
+ object_org_id: null,
47
+ object_name: null,
48
+ object_company_id: null,
49
+ object_company_name: null,
50
+ object_group_id: null,
51
+ object_group_name: null,
52
+ predicate: null,
53
+ edge_family: null,
54
+ edge_scope: null,
55
+ source_key: null,
56
+ evidence_type: null,
57
+ authority_class: null,
58
+ evidence_count: null,
59
+ context_count: null,
60
+ confidence: null,
61
+ first_observed_at: null,
62
+ last_observed_at: null,
63
+ license_name: null,
64
+ attribution: null,
65
+ restriction_tier: null
66
+ )
67
+ ```
68
+
@@ -0,0 +1,58 @@
1
+ # PharmaObservatory::OwnershipPercentagesResponse
2
+
3
+ ## Properties
4
+
5
+ | Name | Type | Description | Notes |
6
+ | ---- | ---- | ----------- | ----- |
7
+ | **dataset** | **String** | | |
8
+ | **grain** | **String** | | [optional] |
9
+ | **object_type** | **String** | | [optional] |
10
+ | **id** | **String** | | [optional] |
11
+ | **scope** | [**BiomarkerAssayEvidenceResponseScope**](BiomarkerAssayEvidenceResponseScope.md) | | [optional] |
12
+ | **columns** | [**Array<DatasetColumn>**](DatasetColumn.md) | | |
13
+ | **rows** | [**Array<OwnershipPercentagesRow>**](OwnershipPercentagesRow.md) | | |
14
+ | **total** | **Integer** | The exact count of the filtered rows on an ungrouped read, carried by the cursor; null when grouped. | [optional] |
15
+ | **next_cursor** | **String** | | [optional] |
16
+ | **sort** | **Array<String>** | | [optional] |
17
+ | **filters** | **Array<Hash<String, Object>>** | | [optional] |
18
+ | **group_by** | **Array<String>** | | [optional] |
19
+ | **measures** | **Array<String>** | | [optional] |
20
+ | **attribution** | [**Array<DatasetAttribution>**](DatasetAttribution.md) | | [optional] |
21
+ | **source_credit** | **String** | | [optional] |
22
+ | **withheld_tiers** | **Array<String>** | | [optional] |
23
+ | **withheld_columns** | **Array<String>** | | [optional] |
24
+ | **freshness** | [**BiomarkerAssayEvidenceResponseFreshness**](BiomarkerAssayEvidenceResponseFreshness.md) | | [optional] |
25
+ | **build** | [**BiomarkerAssayEvidenceResponseBuild**](BiomarkerAssayEvidenceResponseBuild.md) | | [optional] |
26
+ | **build_state** | [**DatasetBuildState**](DatasetBuildState.md) | | [optional] |
27
+ | **restriction** | **Hash<String, Object>** | | [optional] |
28
+
29
+ ## Example
30
+
31
+ ```ruby
32
+ require 'pharmaobservatory'
33
+
34
+ instance = PharmaObservatory::OwnershipPercentagesResponse.new(
35
+ dataset: null,
36
+ grain: null,
37
+ object_type: null,
38
+ id: null,
39
+ scope: null,
40
+ columns: null,
41
+ rows: null,
42
+ total: null,
43
+ next_cursor: null,
44
+ sort: null,
45
+ filters: null,
46
+ group_by: null,
47
+ measures: null,
48
+ attribution: null,
49
+ source_credit: null,
50
+ withheld_tiers: null,
51
+ withheld_columns: null,
52
+ freshness: null,
53
+ build: null,
54
+ build_state: null,
55
+ restriction: null
56
+ )
57
+ ```
58
+
@@ -0,0 +1,74 @@
1
+ # PharmaObservatory::OwnershipPercentagesRow
2
+
3
+ ## Properties
4
+
5
+ | Name | Type | Description | Notes |
6
+ | ---- | ---- | ----------- | ----- |
7
+ | **subject_org_id** | **String** | Legal-entity level: the subject organization's record, a resolution root (the identity every ownership dataset keys on). One row per organization; an insider row with no organization has no row here. | [optional] |
8
+ | **subject_company_id** | **String** | Company level: the subject organization's company (null when the organization does not resolve to a company). | [optional] |
9
+ | **subject_company_name** | **String** | Display name of the subject organization's company. | [optional] |
10
+ | **subject_group_id** | **String** | Group level: the subject organization's current ultimate parent company; a root company's group is itself. | [optional] |
11
+ | **subject_group_name** | **String** | Display name of the subject organization's group. | [optional] |
12
+ | **any_ownership_source** | **Boolean** | True when an insider row or a Form 13F quarter exists for the organization. | [optional] |
13
+ | **shares_outstanding_state** | **String** | reported when the organization has a cover-page share count on file, not_reported when it has none (then no percentage is taken and the share figures are shown instead). | [optional] |
14
+ | **shares_outstanding** | **Float** | The denominator both percentages divide into: the latest cover-page share count (dei:EntityCommonStockSharesOutstanding) from an annual form. It is measured on the filing's cover date, 0 to 3 months after the fiscal period end, and the cover date is not published, so its vintage is the fiscal year in shares_outstanding_fy. | [optional] |
15
+ | **shares_outstanding_fy** | **Integer** | The fiscal year of the filing the share count comes from. | [optional] |
16
+ | **shares_outstanding_concept** | **String** | The XBRL (eXtensible Business Reporting Language) concept the share count is read from. Always dei:EntityCommonStockSharesOutstanding. | [optional] |
17
+ | **insider_state** | **String** | How the insider figure was reached. reported: The sum of the current non-derivative balance each reporting owner last filed on a Form 3, 4 or 5, divided by the share count on file. no_insider_filing: No Form 3, 4 or 5 in our data names an insider of this company. That is a statement about coverage, not a statement that insiders hold nothing. all_positions_closed: Every insider position on file has been reported closed. This is a filed zero, not missing data. derivative_only: The insiders on file hold only derivative positions (options and similar), which are not outstanding shares. This is a filed zero, not missing data. no_denominator: No percentage: this company's SEC filings in our data carry no cover-page share count, so there is no denominator to divide by. The share count on file is shown instead. not_computable: No percentage is taken here. The reported share total is given instead, with the reason no ratio is taken. | [optional] |
18
+ | **insider_reason** | **String** | Why an insider ratio was not taken when insider_state is not_computable. denominator_stale: The share count on file is more than two years older than the positions it would be divided into, so the ratio would not describe this company. exceeds_shares_outstanding: The insider total on file is larger than the company's whole share count, which is arithmetically impossible for a single source and means the filings behind it have not consolidated correctly. Null otherwise. | [optional] |
19
+ | **insider_percent** | **Float** | The share of shares outstanding held by Form 3, 4 and 5 insiders (insider_shares divided by shares_outstanding, times 100, unrounded); null unless insider_state is reported. | [optional] |
20
+ | **insider_shares** | **Float** | The sum of the current non-derivative balance each reporting insider last filed. A ceased or options-only insider adds nothing to it. Null when no insider holds standing shares. | [optional] |
21
+ | **insider_owner_count** | **Integer** | Insiders on file for the organization (0 when none). | [optional] |
22
+ | **insider_standing_owner_count** | **Integer** | Insiders with a positive standing equity balance, the only population insider_shares describes. | [optional] |
23
+ | **insider_closed_owner_count** | **Integer** | Insiders whose standing equity balance is zero or absent: closed positions plus options-only insiders. | [optional] |
24
+ | **insider_derivative_only_owner_count** | **Integer** | Of the closed insiders, those whose only remaining positions are derivatives (options and similar), which are not outstanding shares. | [optional] |
25
+ | **insider_last_filing_date** | **Date** | The latest filing date among the organization's insider rows. | [optional] |
26
+ | **institutional_state** | **String** | How the institutional figure was reached. reported: Every position reported on Form 13F for the quarter shown, summed once per filing manager, against the same share count as the insider figure. exceeds_outstanding: Reported positions exceed the shares outstanding on file. Shown as filed. implausible: No percentage: reported positions exceed 1.5 times the shares outstanding on file, which indicates a corporate action or a denominator mismatch rather than ownership. no_13f_issuer: No Form 13F issuer resolved to this company in any quarter. Positions are reported against a SECURITY, so this is a statement about the CUSIP-to-company bridge, not about institutional interest. no_reference_period: No manager reported this company for the most recent fully-reported quarter. Positions in earlier quarters are on file and are reported per manager, but a manager whose newest filing is for an older quarter is not a current holder and is not counted here. no_reference_shares: No manager reported an equity position in this company for the most recent fully-reported quarter. Only options, debt or non-equity issues were reported, and none of those is a share count. no_denominator: No percentage: this company's SEC filings in our data carry no cover-page share count, so there is no denominator to divide by. The reported share total is shown instead. not_computable: No percentage is taken here. The reported share total is given instead, with the reason no ratio is taken. | [optional] |
27
+ | **institutional_reason** | **String** | Why an institutional ratio was not taken when institutional_state is not_computable. denominator_stale: The share count on file is more than two years older than the positions it would be divided into, so the ratio would not describe this company. Null otherwise. | [optional] |
28
+ | **institutional_percent** | **Float** | The share of shares outstanding under reported institutional discretion at the reference quarter (institutional_shares_reported divided by shares_outstanding, times 100, unrounded, as filed and never capped); null unless institutional_state is reported or exceeds_outstanding. | [optional] |
29
+ | **institutional_shares_reported** | **Float** | The shares reported on Form 13F at the reference quarter, counted equity positions only, summed once per filing manager. Null when the organization has no reference-quarter row. | [optional] |
30
+ | **institutional_manager_count** | **Integer** | Managers reporting a counted equity position at the reference quarter (0 when there is no reference-quarter row). | [optional] |
31
+ | **institutional_report_period** | **Date** | The reference quarter end the institutional figure is measured at: the most recent quarter in which at least 80 percent of the prior quarter's filing managers had filed. | [optional] |
32
+ | **institutional_shares_otr** | **Float** | Of institutional_shares_reported, the shares under other (OTR) discretion. | [optional] |
33
+ | **institutional_shares_excluded_non_equity_issue** | **Float** | Shares reported against convertible notes, debt and preferred issues at the reference quarter, excluded from institutional_shares_reported. | [optional] |
34
+ | **institutional_equity_cusip_count** | **Integer** | Distinct equity CUSIPs (Committee on Uniform Securities Identification Procedures identifiers) counted at the reference quarter (0 when there is no reference-quarter row). | [optional] |
35
+ | **institutional_latest_filing_date** | **Date** | The latest Form 13F filing date among the reference quarter's positions. | [optional] |
36
+
37
+ ## Example
38
+
39
+ ```ruby
40
+ require 'pharmaobservatory'
41
+
42
+ instance = PharmaObservatory::OwnershipPercentagesRow.new(
43
+ subject_org_id: null,
44
+ subject_company_id: null,
45
+ subject_company_name: null,
46
+ subject_group_id: null,
47
+ subject_group_name: null,
48
+ any_ownership_source: null,
49
+ shares_outstanding_state: null,
50
+ shares_outstanding: null,
51
+ shares_outstanding_fy: null,
52
+ shares_outstanding_concept: null,
53
+ insider_state: null,
54
+ insider_reason: null,
55
+ insider_percent: null,
56
+ insider_shares: null,
57
+ insider_owner_count: null,
58
+ insider_standing_owner_count: null,
59
+ insider_closed_owner_count: null,
60
+ insider_derivative_only_owner_count: null,
61
+ insider_last_filing_date: null,
62
+ institutional_state: null,
63
+ institutional_reason: null,
64
+ institutional_percent: null,
65
+ institutional_shares_reported: null,
66
+ institutional_manager_count: null,
67
+ institutional_report_period: null,
68
+ institutional_shares_otr: null,
69
+ institutional_shares_excluded_non_equity_issue: null,
70
+ institutional_equity_cusip_count: null,
71
+ institutional_latest_filing_date: null
72
+ )
73
+ ```
74
+
@@ -8,7 +8,7 @@
8
8
  | **grain** | **String** | | [optional] |
9
9
  | **object_type** | **String** | | [optional] |
10
10
  | **id** | **String** | | [optional] |
11
- | **scope** | [**BiomarkerCdxAssertionsResponseScope**](BiomarkerCdxAssertionsResponseScope.md) | | [optional] |
11
+ | **scope** | [**BiomarkerAssayEvidenceResponseScope**](BiomarkerAssayEvidenceResponseScope.md) | | [optional] |
12
12
  | **columns** | [**Array<DatasetColumn>**](DatasetColumn.md) | | |
13
13
  | **rows** | [**Array<OwnershipPositionsRow>**](OwnershipPositionsRow.md) | | |
14
14
  | **total** | **Integer** | The exact count of the filtered rows on an ungrouped read, carried by the cursor; null when grouped. | [optional] |
@@ -21,8 +21,8 @@
21
21
  | **source_credit** | **String** | | [optional] |
22
22
  | **withheld_tiers** | **Array<String>** | | [optional] |
23
23
  | **withheld_columns** | **Array<String>** | | [optional] |
24
- | **freshness** | [**BiomarkerCdxAssertionsResponseFreshness**](BiomarkerCdxAssertionsResponseFreshness.md) | | [optional] |
25
- | **build** | [**BiomarkerCdxAssertionsResponseBuild**](BiomarkerCdxAssertionsResponseBuild.md) | | [optional] |
24
+ | **freshness** | [**BiomarkerAssayEvidenceResponseFreshness**](BiomarkerAssayEvidenceResponseFreshness.md) | | [optional] |
25
+ | **build** | [**BiomarkerAssayEvidenceResponseBuild**](BiomarkerAssayEvidenceResponseBuild.md) | | [optional] |
26
26
  | **build_state** | [**DatasetBuildState**](DatasetBuildState.md) | | [optional] |
27
27
  | **restriction** | **Hash<String, Object>** | | [optional] |
28
28
 
@@ -4,8 +4,8 @@
4
4
 
5
5
  | Name | Type | Description | Notes |
6
6
  | ---- | ---- | ----------- | ----- |
7
- | **position_id** | **String** | The position id. For a position whose owner name is withheld it is an opaque handle that derives nothing from the owner and is stable only while the other positions of the same owned company, filing family and dimension are unchanged. | [optional] |
8
- | **source_class** | **String** | The filing family: sec_forms_3_4_5 (insiders), sec_schedules_13d_g (beneficial owners), sec_form_adv (investment adviser control persons) or sec_def_14a (proxy-statement tables). | [optional] |
7
+ | **position_id** | **String** | The position id (the owner rollup id). | [optional] |
8
+ | **source_class** | **String** | The filing family: sec_forms_3_4_5 (insiders), sec_schedules_13d_g (beneficial owners), sec_form_adv (investment adviser control persons), sec_def_14a (proxy-statement tables) or wikidata (ownership statements in Wikidata). | [optional] |
9
9
  | **ownership_dimension** | **String** | What the position measures: insider_reporting, beneficial_ownership, voting_power, economic_interest or control. Positions of different dimensions are different measurements and are not added. | [optional] |
10
10
  | **relationship_type** | **String** | The owner's relationship to the company as the filing family states it. | [optional] |
11
11
  | **subject_name** | **String** | The owned company as filed. | [optional] |
@@ -14,16 +14,17 @@
14
14
  | **subject_company_name** | **String** | Display name of the owned company. | [optional] |
15
15
  | **subject_group_id** | **String** | Group level: the owned company's current ultimate parent; a root's group is itself. | [optional] |
16
16
  | **subject_group_name** | **String** | Display name of the owned company's group. | [optional] |
17
- | **owner_name** | **String** | The owner's name as filed. Null for an owner whose filing does not mark the name public (see owner_name_is_public). | [optional] |
18
- | **owner_name_is_public** | **Boolean** | True when the filing marks the owner's name public. When false every column that could identify the owner is null (name, identity key, person id, investor id, organization and company columns, source_url and the dates); the position and its figures stay. | [optional] |
17
+ | **subject_investor_id** | **String** | The key of the owned party in the investor directory when it is an investor (null otherwise). Filter on it for who is reported to own or control an investor. | [optional] |
18
+ | **owner_name** | **String** | The owner's name as filed. | [optional] |
19
+ | **owner_name_is_public** | **Boolean** | A label, not a gate: true when the filing marks the owner's privacy status public. It does not affect any other column; the owner's name, identity key and every other field below are populated whatever this value is. | [optional] |
19
20
  | **owner_kind** | **String** | What the owner is: organization, natural_person, reporting_group or unknown. | [optional] |
20
- | **owner_identity_key** | **String** | The owner's stable identity (an SEC registration number or an adviser registration number); null when the name is withheld. | [optional] |
21
- | **owner_person_id** | **String** | The key of an owner who is a natural person; null for other owners and when the name is withheld. | [optional] |
22
- | **owner_investor_id** | **String** | The key of the owner in the investor directory when it is one; null when the name is withheld. | [optional] |
23
- | **owner_org_id** | **String** | Legal-entity level: the owner's organization record (null when the owner is not an organization, is unresolved or is withheld). | [optional] |
24
- | **owner_company_id** | **String** | Company level: the owner's company (null when unresolved or when the name is withheld). | [optional] |
21
+ | **owner_identity_key** | **String** | The owner's stable identity (an SEC registration number or an adviser registration number). | [optional] |
22
+ | **owner_person_id** | **String** | The key of an owner who is a natural person; null for other owners. | [optional] |
23
+ | **owner_investor_id** | **String** | The key of the owner in the investor directory when it is one. | [optional] |
24
+ | **owner_org_id** | **String** | Legal-entity level: the owner's organization record (null when the owner is not an organization or is unresolved). | [optional] |
25
+ | **owner_company_id** | **String** | Company level: the owner's company (null when unresolved). | [optional] |
25
26
  | **owner_company_name** | **String** | Display name of the owner's company. | [optional] |
26
- | **owner_group_id** | **String** | Group level: the owner's current ultimate parent; a root's group is itself (null when the owner is withheld). | [optional] |
27
+ | **owner_group_id** | **String** | Group level: the owner's current ultimate parent; a root's group is itself. | [optional] |
27
28
  | **owner_group_name** | **String** | Display name of the owner's group. | [optional] |
28
29
  | **shares_basis** | **String** | How the share figure was reached: sum_standing_balances (insider balances), group_reported_maximum (a joint filing's maximum, never a sum of its filers) or no_quantity (the source gives none). Read a share figure with its basis. | [optional] |
29
30
  | **shares** | **Float** | Shares the owner holds, on the shares_basis. Null when the source gives no quantity. | [optional] |
@@ -40,10 +41,10 @@
40
41
  | **standing_position_count** | **Integer** | Of those, positions still standing. | [optional] |
41
42
  | **ceased_position_count** | **Integer** | Of those, positions reported ceased. | [optional] |
42
43
  | **no_longer_reported_position_count** | **Integer** | Of those, positions the filer no longer reports. | [optional] |
43
- | **first_observed_date** | **Date** | Date the position was first reported; null when the owner's name is withheld. | [optional] |
44
- | **last_activity_date** | **Date** | Date of the latest reported activity; null when the owner's name is withheld. | [optional] |
45
- | **last_filing_date** | **Date** | Date of the latest filing; null when the owner's name is withheld. | [optional] |
46
- | **source_url** | **String** | A link to the latest filing; null when the owner's name is withheld, because the filing names the owner. | [optional] |
44
+ | **first_observed_date** | **Date** | Date the position was first reported. | [optional] |
45
+ | **last_activity_date** | **Date** | Date of the latest reported activity. | [optional] |
46
+ | **last_filing_date** | **Date** | Date of the latest filing. | [optional] |
47
+ | **source_url** | **String** | A link to the latest filing. | [optional] |
47
48
  | **contains_personal_data** | **Boolean** | True when the row names a natural person. | [optional] |
48
49
  | **privacy_status** | **String** | The filing's privacy status for the owner: not_applicable, pending_review, approved_public_fields, restricted or protected. | [optional] |
49
50
 
@@ -63,6 +64,7 @@ instance = PharmaObservatory::OwnershipPositionsRow.new(
63
64
  subject_company_name: null,
64
65
  subject_group_id: null,
65
66
  subject_group_name: null,
67
+ subject_investor_id: null,
66
68
  owner_name: null,
67
69
  owner_name_is_public: null,
68
70
  owner_kind: null,
@@ -8,7 +8,7 @@
8
8
  | **grain** | **String** | | [optional] |
9
9
  | **object_type** | **String** | | [optional] |
10
10
  | **id** | **String** | | [optional] |
11
- | **scope** | [**BiomarkerCdxAssertionsResponseScope**](BiomarkerCdxAssertionsResponseScope.md) | | [optional] |
11
+ | **scope** | [**BiomarkerAssayEvidenceResponseScope**](BiomarkerAssayEvidenceResponseScope.md) | | [optional] |
12
12
  | **columns** | [**Array<DatasetColumn>**](DatasetColumn.md) | | |
13
13
  | **rows** | [**Array<PdufaDatesRow>**](PdufaDatesRow.md) | | |
14
14
  | **total** | **Integer** | The exact count of the filtered rows on an ungrouped read, carried by the cursor; null when grouped. | [optional] |
@@ -21,8 +21,8 @@
21
21
  | **source_credit** | **String** | | [optional] |
22
22
  | **withheld_tiers** | **Array<String>** | | [optional] |
23
23
  | **withheld_columns** | **Array<String>** | | [optional] |
24
- | **freshness** | [**BiomarkerCdxAssertionsResponseFreshness**](BiomarkerCdxAssertionsResponseFreshness.md) | | [optional] |
25
- | **build** | [**BiomarkerCdxAssertionsResponseBuild**](BiomarkerCdxAssertionsResponseBuild.md) | | [optional] |
24
+ | **freshness** | [**BiomarkerAssayEvidenceResponseFreshness**](BiomarkerAssayEvidenceResponseFreshness.md) | | [optional] |
25
+ | **build** | [**BiomarkerAssayEvidenceResponseBuild**](BiomarkerAssayEvidenceResponseBuild.md) | | [optional] |
26
26
  | **build_state** | [**DatasetBuildState**](DatasetBuildState.md) | | [optional] |
27
27
  | **restriction** | **Hash<String, Object>** | | [optional] |
28
28
 
@@ -16,7 +16,7 @@
16
16
  | **event_category** | **String** | Event category (pdufa, adcomm and so on). | [optional] |
17
17
  | **drug_name** | **String** | The drug name as filed. | [optional] |
18
18
  | **drug_id** | **String** | The drug key. | [optional] |
19
- | **molecule_id** | **String** | The molecule key. | [optional] |
19
+ | **molecule_id** | **String** | The molecule key, the resolved drug of the calendar entry and the entry key for the drugs object type (null when the drug name did not resolve to a drug). | [optional] |
20
20
  | **sponsor_name** | **String** | The sponsor name as filed. | [optional] |
21
21
  | **sponsor_org_id** | **String** | Legal-entity level: the organization record the sponsor resolved to (null when unresolved). | [optional] |
22
22
  | **sponsor_company_id** | **String** | Company level: the company the sponsor belongs to (null when unresolved). | [optional] |
@@ -0,0 +1,58 @@
1
+ # PharmaObservatory::ProgramLicensingCandidatesResponse
2
+
3
+ ## Properties
4
+
5
+ | Name | Type | Description | Notes |
6
+ | ---- | ---- | ----------- | ----- |
7
+ | **dataset** | **String** | | |
8
+ | **grain** | **String** | | [optional] |
9
+ | **object_type** | **String** | | [optional] |
10
+ | **id** | **String** | | [optional] |
11
+ | **scope** | [**BiomarkerAssayEvidenceResponseScope**](BiomarkerAssayEvidenceResponseScope.md) | | [optional] |
12
+ | **columns** | [**Array<DatasetColumn>**](DatasetColumn.md) | | |
13
+ | **rows** | [**Array<ProgramLicensingCandidatesRow>**](ProgramLicensingCandidatesRow.md) | | |
14
+ | **total** | **Integer** | The exact count of the filtered rows on an ungrouped read, carried by the cursor; null when grouped. | [optional] |
15
+ | **next_cursor** | **String** | | [optional] |
16
+ | **sort** | **Array<String>** | | [optional] |
17
+ | **filters** | **Array<Hash<String, Object>>** | | [optional] |
18
+ | **group_by** | **Array<String>** | | [optional] |
19
+ | **measures** | **Array<String>** | | [optional] |
20
+ | **attribution** | [**Array<DatasetAttribution>**](DatasetAttribution.md) | | [optional] |
21
+ | **source_credit** | **String** | | [optional] |
22
+ | **withheld_tiers** | **Array<String>** | | [optional] |
23
+ | **withheld_columns** | **Array<String>** | | [optional] |
24
+ | **freshness** | [**BiomarkerAssayEvidenceResponseFreshness**](BiomarkerAssayEvidenceResponseFreshness.md) | | [optional] |
25
+ | **build** | [**BiomarkerAssayEvidenceResponseBuild**](BiomarkerAssayEvidenceResponseBuild.md) | | [optional] |
26
+ | **build_state** | [**DatasetBuildState**](DatasetBuildState.md) | | [optional] |
27
+ | **restriction** | **Hash<String, Object>** | | [optional] |
28
+
29
+ ## Example
30
+
31
+ ```ruby
32
+ require 'pharmaobservatory'
33
+
34
+ instance = PharmaObservatory::ProgramLicensingCandidatesResponse.new(
35
+ dataset: null,
36
+ grain: null,
37
+ object_type: null,
38
+ id: null,
39
+ scope: null,
40
+ columns: null,
41
+ rows: null,
42
+ total: null,
43
+ next_cursor: null,
44
+ sort: null,
45
+ filters: null,
46
+ group_by: null,
47
+ measures: null,
48
+ attribution: null,
49
+ source_credit: null,
50
+ withheld_tiers: null,
51
+ withheld_columns: null,
52
+ freshness: null,
53
+ build: null,
54
+ build_state: null,
55
+ restriction: null
56
+ )
57
+ ```
58
+
@@ -0,0 +1,58 @@
1
+ # PharmaObservatory::ProgramLicensingCandidatesRow
2
+
3
+ ## Properties
4
+
5
+ | Name | Type | Description | Notes |
6
+ | ---- | ---- | ----------- | ----- |
7
+ | **sponsor_org_id** | **String** | Legal-entity level: the lead sponsor's organization record. | [optional] |
8
+ | **sponsor_name** | **String** | The sponsor's organization name. | [optional] |
9
+ | **sponsor_company_id** | **String** | Company level: the sponsor's company (null when unresolved). | [optional] |
10
+ | **sponsor_company_name** | **String** | Display name of the sponsor's company. | [optional] |
11
+ | **sponsor_group_id** | **String** | Group level: the sponsor's current ultimate parent; a root's group is itself. | [optional] |
12
+ | **sponsor_group_name** | **String** | Display name of the sponsor's group. | [optional] |
13
+ | **drug_id** | **String** | The drug key. | [optional] |
14
+ | **drug_name** | **String** | The drug's name. | [optional] |
15
+ | **condition_id** | **String** | The condition key, a MeSH (Medical Subject Headings) descriptor id (D followed by six to nine digits). | [optional] |
16
+ | **condition_name** | **String** | The condition's name. | [optional] |
17
+ | **condition_ancestor_ids** | **Array<String>** | Every MeSH descriptor id at or above the condition in the tree, the condition itself included. Filter a subtree with = ANY. | [optional] |
18
+ | **max_phase** | **Integer** | Highest phase reached: 0 early phase 1 through 6 for phase 4 (marketed); -1 when unstated. | [optional] |
19
+ | **n_trials** | **Integer** | Lead-sponsored trials in the program. | [optional] |
20
+ | **n_active** | **Integer** | Of those, trials in an active status. | [optional] |
21
+ | **last_year** | **Integer** | Latest trial start year. | [optional] |
22
+ | **last_update_year** | **Integer** | Year the program's most recently updated trial record was posted. | [optional] |
23
+ | **withdrawn** | **Boolean** | True when the drug has been withdrawn. | [optional] |
24
+ | **cause_name** | **String** | The Global Burden of Disease cause matched to the condition. | [optional] |
25
+ | **dalys_millions** | **Float** | Global disability-adjusted life years for the matched cause, in millions. | [optional] |
26
+ | **deaths_millions** | **Float** | Global deaths for the matched cause, in millions. | [optional] |
27
+ | **druggability** | **Integer** | Druggability class of the matched cause: 1 highly druggable, 2 druggable, 3 challenging, 4 very challenging. | [optional] |
28
+
29
+ ## Example
30
+
31
+ ```ruby
32
+ require 'pharmaobservatory'
33
+
34
+ instance = PharmaObservatory::ProgramLicensingCandidatesRow.new(
35
+ sponsor_org_id: null,
36
+ sponsor_name: null,
37
+ sponsor_company_id: null,
38
+ sponsor_company_name: null,
39
+ sponsor_group_id: null,
40
+ sponsor_group_name: null,
41
+ drug_id: null,
42
+ drug_name: null,
43
+ condition_id: null,
44
+ condition_name: null,
45
+ condition_ancestor_ids: null,
46
+ max_phase: null,
47
+ n_trials: null,
48
+ n_active: null,
49
+ last_year: null,
50
+ last_update_year: null,
51
+ withdrawn: null,
52
+ cause_name: null,
53
+ dalys_millions: null,
54
+ deaths_millions: null,
55
+ druggability: null
56
+ )
57
+ ```
58
+
@@ -0,0 +1,58 @@
1
+ # PharmaObservatory::ProgramsResponse
2
+
3
+ ## Properties
4
+
5
+ | Name | Type | Description | Notes |
6
+ | ---- | ---- | ----------- | ----- |
7
+ | **dataset** | **String** | | |
8
+ | **grain** | **String** | | [optional] |
9
+ | **object_type** | **String** | | [optional] |
10
+ | **id** | **String** | | [optional] |
11
+ | **scope** | [**BiomarkerAssayEvidenceResponseScope**](BiomarkerAssayEvidenceResponseScope.md) | | [optional] |
12
+ | **columns** | [**Array<DatasetColumn>**](DatasetColumn.md) | | |
13
+ | **rows** | [**Array<ProgramsRow>**](ProgramsRow.md) | | |
14
+ | **total** | **Integer** | The exact count of the filtered rows on an ungrouped read, carried by the cursor; null when grouped. | [optional] |
15
+ | **next_cursor** | **String** | | [optional] |
16
+ | **sort** | **Array<String>** | | [optional] |
17
+ | **filters** | **Array<Hash<String, Object>>** | | [optional] |
18
+ | **group_by** | **Array<String>** | | [optional] |
19
+ | **measures** | **Array<String>** | | [optional] |
20
+ | **attribution** | [**Array<DatasetAttribution>**](DatasetAttribution.md) | | [optional] |
21
+ | **source_credit** | **String** | | [optional] |
22
+ | **withheld_tiers** | **Array<String>** | | [optional] |
23
+ | **withheld_columns** | **Array<String>** | | [optional] |
24
+ | **freshness** | [**BiomarkerAssayEvidenceResponseFreshness**](BiomarkerAssayEvidenceResponseFreshness.md) | | [optional] |
25
+ | **build** | [**BiomarkerAssayEvidenceResponseBuild**](BiomarkerAssayEvidenceResponseBuild.md) | | [optional] |
26
+ | **build_state** | [**DatasetBuildState**](DatasetBuildState.md) | | [optional] |
27
+ | **restriction** | **Hash<String, Object>** | | [optional] |
28
+
29
+ ## Example
30
+
31
+ ```ruby
32
+ require 'pharmaobservatory'
33
+
34
+ instance = PharmaObservatory::ProgramsResponse.new(
35
+ dataset: null,
36
+ grain: null,
37
+ object_type: null,
38
+ id: null,
39
+ scope: null,
40
+ columns: null,
41
+ rows: null,
42
+ total: null,
43
+ next_cursor: null,
44
+ sort: null,
45
+ filters: null,
46
+ group_by: null,
47
+ measures: null,
48
+ attribution: null,
49
+ source_credit: null,
50
+ withheld_tiers: null,
51
+ withheld_columns: null,
52
+ freshness: null,
53
+ build: null,
54
+ build_state: null,
55
+ restriction: null
56
+ )
57
+ ```
58
+
@@ -0,0 +1,46 @@
1
+ # PharmaObservatory::ProgramsRow
2
+
3
+ ## Properties
4
+
5
+ | Name | Type | Description | Notes |
6
+ | ---- | ---- | ----------- | ----- |
7
+ | **program_id** | **String** | The program key: a hash of drug_id and condition_id, one value per row. | [optional] |
8
+ | **drug_id** | **String** | The drug key of the program, the drug record the trials name (a salt form or a trial arm is its own record). | [optional] |
9
+ | **molecule_id** | **String** | The molecule key: the resolved drug the program's drug record folds to, and the entry key for the drugs object type. | [optional] |
10
+ | **drug_name** | **String** | The drug's name. | [optional] |
11
+ | **condition_id** | **String** | The condition key, a MeSH (Medical Subject Headings) descriptor id (D followed by six to nine digits). | [optional] |
12
+ | **condition_name** | **String** | The condition's name. | [optional] |
13
+ | **is_indication** | **Boolean** | True for a specific disease, false for a broad MeSH umbrella condition. | [optional] |
14
+ | **max_phase** | **Integer** | Highest phase reached across the program's trials: 0 not reported, 1 through 4 for phase 1 through phase 4 (the 0 to 4 scale; see caveats). | [optional] |
15
+ | **n_trials** | **Integer** | Distinct trials of the program, across all sponsors. | [optional] |
16
+ | **n_completed** | **Integer** | Of those, trials with status completed. | [optional] |
17
+ | **n_terminated** | **Integer** | Of those, trials with status terminated. | [optional] |
18
+ | **first_year** | **Integer** | Earliest plausible trial start year. | [optional] |
19
+ | **last_year** | **Integer** | Latest plausible trial completion or start year. | [optional] |
20
+ | **n_sponsor_companies** | **Integer** | Distinct lead-sponsor companies across the program's trials; an unresolved lead sponsor counts as itself. | [optional] |
21
+ | **dalys_millions** | **Float** | Disability-adjusted life years (DALYs, millions) of the condition's global burden, from the Global Burden of Disease (GBD) 2021 study of the Institute for Health Metrics and Evaluation (IHME). Null for a caller without the licence for this column; see withheld_columns. | [optional] |
22
+
23
+ ## Example
24
+
25
+ ```ruby
26
+ require 'pharmaobservatory'
27
+
28
+ instance = PharmaObservatory::ProgramsRow.new(
29
+ program_id: null,
30
+ drug_id: null,
31
+ molecule_id: null,
32
+ drug_name: null,
33
+ condition_id: null,
34
+ condition_name: null,
35
+ is_indication: null,
36
+ max_phase: null,
37
+ n_trials: null,
38
+ n_completed: null,
39
+ n_terminated: null,
40
+ first_year: null,
41
+ last_year: null,
42
+ n_sponsor_companies: null,
43
+ dalys_millions: null
44
+ )
45
+ ```
46
+
@@ -0,0 +1,58 @@
1
+ # PharmaObservatory::RareDiseaseGenesResponse
2
+
3
+ ## Properties
4
+
5
+ | Name | Type | Description | Notes |
6
+ | ---- | ---- | ----------- | ----- |
7
+ | **dataset** | **String** | | |
8
+ | **grain** | **String** | | [optional] |
9
+ | **object_type** | **String** | | [optional] |
10
+ | **id** | **String** | | [optional] |
11
+ | **scope** | [**BiomarkerAssayEvidenceResponseScope**](BiomarkerAssayEvidenceResponseScope.md) | | [optional] |
12
+ | **columns** | [**Array<DatasetColumn>**](DatasetColumn.md) | | |
13
+ | **rows** | [**Array<RareDiseaseGenesRow>**](RareDiseaseGenesRow.md) | | |
14
+ | **total** | **Integer** | The exact count of the filtered rows on an ungrouped read, carried by the cursor; null when grouped. | [optional] |
15
+ | **next_cursor** | **String** | | [optional] |
16
+ | **sort** | **Array<String>** | | [optional] |
17
+ | **filters** | **Array<Hash<String, Object>>** | | [optional] |
18
+ | **group_by** | **Array<String>** | | [optional] |
19
+ | **measures** | **Array<String>** | | [optional] |
20
+ | **attribution** | [**Array<DatasetAttribution>**](DatasetAttribution.md) | | [optional] |
21
+ | **source_credit** | **String** | | [optional] |
22
+ | **withheld_tiers** | **Array<String>** | | [optional] |
23
+ | **withheld_columns** | **Array<String>** | | [optional] |
24
+ | **freshness** | [**BiomarkerAssayEvidenceResponseFreshness**](BiomarkerAssayEvidenceResponseFreshness.md) | | [optional] |
25
+ | **build** | [**BiomarkerAssayEvidenceResponseBuild**](BiomarkerAssayEvidenceResponseBuild.md) | | [optional] |
26
+ | **build_state** | [**DatasetBuildState**](DatasetBuildState.md) | | [optional] |
27
+ | **restriction** | **Hash<String, Object>** | | [optional] |
28
+
29
+ ## Example
30
+
31
+ ```ruby
32
+ require 'pharmaobservatory'
33
+
34
+ instance = PharmaObservatory::RareDiseaseGenesResponse.new(
35
+ dataset: null,
36
+ grain: null,
37
+ object_type: null,
38
+ id: null,
39
+ scope: null,
40
+ columns: null,
41
+ rows: null,
42
+ total: null,
43
+ next_cursor: null,
44
+ sort: null,
45
+ filters: null,
46
+ group_by: null,
47
+ measures: null,
48
+ attribution: null,
49
+ source_credit: null,
50
+ withheld_tiers: null,
51
+ withheld_columns: null,
52
+ freshness: null,
53
+ build: null,
54
+ build_state: null,
55
+ restriction: null
56
+ )
57
+ ```
58
+